HC Wainwright & Co. Maintains Buy on TG Therapeutics, Raises Price Target to $49
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Edward White has maintained a Buy rating on TG Therapeutics (NASDAQ:TGTX) and increased the price target from $45 to $49.
May 02, 2024 | 5:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Buy rating on TG Therapeutics, raising the price target from $45 to $49.
The increase in price target by HC Wainwright & Co. reflects a positive outlook on TG Therapeutics, likely due to strong company fundamentals or potential market growth. This endorsement from a reputable analyst could lead to increased investor confidence and a potential short-term price increase.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100